Aura Biosciences, Inc.

What they do

Aura Biosciences is developing precision therapies for solid tumors designed to preserve organ function. Its lead candidate, bel-sar, is a virus-like drug conjugate (VDC) that delivers a light-activated cytotoxic payload to tumor cells. Bel-sar is in late-stage clinical development for early choroidal melanoma and also in clinical development for metastases to the choroid, cancers of the ocular surface, and bladder cancer. The company has no approved products and does not generate revenue.

Revenue drivers

• No approved products — Aura has no commercial products; all revenue is currently zero, with potential future revenue dependent on regulatory approval of bel-sar.
• Bel-sar for early choroidal melanoma — Lead pipeline candidate in Phase 3 CoMpass trial, fully enrolled with 108 patients; if approved, could be the first FDA-approved frontline vision-preserving therapy in this indication.
• Bel-sar for other ocular oncology indications — Expanding clinical development in metastases to the choroid (Phase 2) and cancers of the ocular surface (Phase 1 proof-of-concept), with increased resources allocated.
• Bel-sar for bladder cancer (NMIBC) — Ongoing Phase 1b/2 study in non-muscle invasive bladder cancer, but program is being strategically deprioritized to focus resources on ocular oncology.

Recent performance

For the second quarter ended June 30, 2026, Aura reported total assets of $348.1 million, total liabilities of $32.9 million, and cash and equivalents of $67.8 million. Annual net losses have grown from $35.3 million in 2021 to $106.2 million in 2025, with diluted EPS deteriorating from $-8.95 to $-1.76 over the same period. Operating cash flow was consistently negative, reaching $-84.7 million in 2025. The company has an accumulated deficit of $480.4 million as of December 31, 2025.

Strategy

Aura has refined its strategic operating plan to focus on the development of bel-sar in ocular oncology, specifically early choroidal melanoma, metastases to the choroid, and cancers of the ocular surface. The company has reduced its workforce by approximately 20% as part of an organizational restructuring to align resources with this ocular oncology focus. The NMIBC program is being deprioritized, with data collection through the 12-month follow-up period to be completed to preserve optionality. The company is also strengthening its leadership with new executives in COO, CQO, and CPO roles to support next-stage growth.

Risks

• Going concern risk — The company has incurred significant net losses since inception and expects to continue losses, raising substantial doubt about its ability to continue as a going concern.
• Clinical development risk — Bel-sar is in late-stage trials; failure to demonstrate safety and efficacy in the Phase 3 CoMpass trial or other studies could prevent regulatory approval.
• Regulatory approval risk — No FDA-approved drug therapies currently exist for early choroidal melanoma; bel-sar must meet regulatory standards to gain approval and commercialize.
• Cash runway risk — With cash and equivalents of $67.8 million and ongoing losses, the company's extended cash runway into 1H 2029 depends on disciplined capital allocation and may require additional financing.

Outlook

Management expects topline data from the Phase 3 CoMpass trial in the second half of 2027, with the trial fully enrolled at 108 patients. The company expects to provide updates on the metastases to the choroid and ocular surface programs, including study completion guidance, in Q1 2027. The strategic refocus on ocular oncology aims to extend the cash runway into 1H 2029.